

Table O.38: Ginkgo biloba (plus risperidone) versus placebo (plus risperidone) in children and young people

Quality assessment							Summary of findings				
Participants (studies) Follow up	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Overall quality of evidence	Study event rates (%)		Relative effect (95% CI)	Anticipated absolute effects	
							With placebo plus risperidone	With ginkgo biloba plus risperidone		Risk with placebo plus risperidone	Risk difference with ginkgo biloba plus risperidone (95% CI)
Targeted behaviour that challenges (severity) – post-treatment (Better indicated by lower values)											
47 (1 study)	no serious risk of bias	no serious inconsistency	serious ¹	very serious ²	undetected	⊕⊖⊖⊖ VERY LOW ^{1,2} due to indirectness, imprecision	24	23	-		The mean targeted behaviour that challenges (severity) – post-treatment in the intervention groups was 0.1 standard deviations higher (0.47 lower to 0.67 higher)

Quality assessment						Summary of findings					
Adverse events (drowsiness, non-occurrence) – post-treatment											
47 (1 study)	no serious risk of bias	no serious inconsistency	serious ¹	very serious ²	undetected	⊕⊖⊖⊖ VERY LOW ^{1,2} due to indirectness, imprecision	17/24 (70.8%)	17/23 (73.9%)	RR 1.04 (0.73 to 1.49)	708 per 1000	28 more per 1000 (from 191 fewer to 347 more)
¹ Applicability – different populations ² Optimal information size not met; small, single study											